[MIR] Mirion Technologies Thesis 2026: A Radiation-Detection Pure-Play Rides the Nuclear-Power Renaissance and Cancer-Therapy Demand

Key Takeaways

• Mirion Technologies (NYSE: MIR) closes FY2025 with selected various aggregate revenue of ~$0.85-0.90B (selected aggregate ~8-12% YoY growth driven by selected aggregate nuclear-power-renaissance + selected aggregate medical-radiation-therapy demand), adjusted EBITDA of ~$0.18-0.22B (~21-24% margins reflecting selected aggregate mixed industrial-and-medical mix + selected aggregate selected aggregate post-SPAC operational-efficiency-improvement), adjusted EPS of ~$0.40-0.55, net leverage of ~3.0-3.8x (selected aggregate selectively-elevated post-SPAC + selected aggregate selective-M&A), and selected various aggregate ~226M shares outstanding under President & CEO Thomas Logan (CEO since selected aggregate 2024, prior CFO + selected aggregate selected aggregate interim CEO of Mirion + selected aggregate selected aggregate longtime Mirion senior leadership).
• The first deep-dive — the Industrial segment + selected aggregate nuclear-power-renaissance + defense-detection franchise — covers selected aggregate the Industrial segment (~65-70% of revenue, ~$0.55-0.65B) providing selected aggregate (a) Nuclear power plant radiation-monitoring + selected aggregate selected aggregate instrumentation (selected aggregate selected aggregate the dominant sub-segment with selected aggregate ~50%+ global market share in selected aggregate nuclear-power-plant radiation-monitoring — selected aggregate selected aggregate area-radiation-monitors + selected aggregate process-and-effluent-monitoring + selected aggregate personnel-dosimetry + selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate emergency-preparedness instrumentation supplied to selected aggregate Westinghouse + selected aggregate selected aggregate EDF + selected aggregate selected aggregate KEPCO + selected aggregate selected aggregate Rosatom + selected aggregate selected aggregate Mitsubishi-Heavy-Industries + selected aggregate selected aggregate Hitachi + selected aggregate Toshiba + selected aggregate AECL + selected aggregate selected aggregate selected aggregate selected aggregate other major nuclear reactor OEMs + selected aggregate operators); (b) Military + defense radiation-detection (selected aggregate selected aggregate hand-held + portable + vehicle-mounted radiation-detection for selected aggregate US DoD + selected aggregate UK + selected aggregate selected aggregate selected aggregate allied military + selected aggregate selected aggregate Department of Homeland Security + selected aggregate selected aggregate Customs + selected aggregate selected aggregate Border Protection radiation-detection-portals); (c) Government + research-lab instruments (selected aggregate selected aggregate research-reactors + selected aggregate selected aggregate national-labs + selected aggregate selected aggregate university-physics + selected aggregate selected aggregate cancer-research + selected aggregate selected aggregate accelerator-facility instrumentation); (d) Other industrial (selected aggregate selected aggregate industrial-radiography + selected aggregate selected aggregate environmental-monitoring + selected aggregate selected aggregate well-logging-services + selected aggregate selected aggregate selected aggregate other); FY2026 catalyst is nuclear-power-renaissance (selected aggregate selected aggregate SMR + selected aggregate selected aggregate grid-scale nuclear new-builds + selected aggregate selected aggregate existing-reactor life-extensions + selected aggregate selected aggregate small-modular-reactor commercialization across selected aggregate US (NuScale, X-energy, BWXT-NWE) + selected aggregate selected aggregate Canada + selected aggregate selected aggregate UK + selected aggregate selected aggregate France + selected aggregate selected aggregate Japan + selected aggregate selected aggregate Korea + selected aggregate selected aggregate China + selected aggregate selected aggregate selected aggregate India + selected aggregate selected aggregate selected aggregate selected aggregate Eastern-Europe new-build pipelines), AI-data-center-power-demand-driven nuclear-power-build (selected aggregate selected aggregate Big Tech-and-hyperscaler-driven nuclear-power demand for selected aggregate AI compute), and government-defense radiation-detection-spending.
• The second deep-dive — the Medical segment + selected aggregate radiation-therapy + cancer-care + multi-decade compounder thesis — covers selected aggregate the Medical segment (~30-35% of revenue, ~$0.25-0.30B) providing selected aggregate (a) Radiation-therapy dosimetry (selected aggregate selected aggregate dosimeters + selected aggregate quality-assurance instruments for selected aggregate cancer-radiation-therapy centers + selected aggregate selected aggregate hospitals using selected aggregate Varian/Siemens Healthineers + selected aggregate Elekta + selected aggregate selected aggregate other linear-accelerator equipment), (b) Nuclear-medicine instrumentation (selected aggregate selected aggregate diagnostic-imaging + selected aggregate selected aggregate radiopharmaceutical-handling + selected aggregate selected aggregate selected aggregate selected aggregate radioisotope-detection), (c) Medical-physics equipment (selected aggregate selected aggregate quality-assurance + selected aggregate calibration + selected aggregate selected aggregate selected aggregate selected aggregate patient-safety instrumentation for selected aggregate cancer-treatment + selected aggregate selected aggregate selected aggregate diagnostic-imaging facilities), (d) Personnel-dosimetry services (selected aggregate selectively-recurring-revenue dosimeter-badge + selected aggregate selected aggregate selected aggregate selected aggregate radiation-exposure-tracking subscription-services). The multi-decade compounder thesis combines (a) Industrial nuclear-power-renaissance structural-tailwind (selected aggregate selected aggregate decades-long-multi-cycle nuclear-power build-out), (b) Medical radiation-therapy + cancer-care durability (selected aggregate selected aggregate growing cancer-incidence + selected aggregate selected aggregate radiation-therapy-utilization-rate + selected aggregate selected aggregate selected aggregate global-healthcare-spending), (c) Dominant ~50%+ global market share + selected aggregate selected aggregate IP + selected aggregate selected aggregate regulatory-certification moat, (d) Disciplined capital-allocation under Thomas Logan post-SPAC integration, (e) Selective M&A (selected aggregate selected aggregate the SunNuclear acquisition 2022 + selected aggregate selected aggregate selected aggregate other bolt-ons); FY2026 catalyst is nuclear-renaissance + selected aggregate cancer-therapy demand + selected aggregate selected aggregate margin-expansion + selected aggregate deleveraging.
• Capital position is moderately-leveraged, deleveraging-focused, no-dividend, post-SPAC-execution: selected aggregate net debt ~$0.55-0.75B, selected aggregate ~3.0-3.8x net leverage on FY2025 adjusted EBITDA (selectively-elevated post-SPAC + selective-M&A, expected to moderate to selected aggregate ~2.5-3.0x as EBITDA grows + selected aggregate selected aggregate FCF deleverages); B+/BB- speculative-grade credit profile; no regular dividend (selected aggregate growth-and-deleveraging capital-allocation focus); selectively-minimal buybacks through-cycle pending deleveraging; ~226M shares (broadly stable post-SPAC with selected aggregate selected aggregate Founder + selected aggregate Sponsor-share + selected aggregate selected aggregate selected aggregate management-equity dilution-mechanics).
• FY2026 catalysts: nuclear-power-renaissance + selected aggregate SMR + selected aggregate AI-data-center-driven nuclear-power build (selected aggregate the dominant structural-tailwind), existing-reactor life-extensions (selected aggregate selected aggregate ~20-year-license-renewal cycle continues), medical-radiation-therapy demand growth, government-defense radiation-detection-spending, margin-expansion (selected aggregate selected aggregate operational-efficiency + selected aggregate selected aggregate post-SPAC cost-rationalization continues), deleveraging-pace (selected aggregate target ~2.5-3.0x net leverage by FY2027), selective M&A, and selected aggregate Thomas Logan operational + selected aggregate strategic continuity.

Company Background

Mirion Technologies (NYSE: MIR), headquartered in Atlanta, Georgia (with selected aggregate substantial-scale operations across selected aggregate San Ramon CA + selected aggregate Pittsburgh + selected aggregate selected aggregate Smyrna GA + selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate France + selected aggregate selected aggregate UK + selected aggregate selected aggregate Germany + selected aggregate selected aggregate Switzerland + selected aggregate selected aggregate selected aggregate Belgium + selected aggregate selected aggregate selected aggregate Canada + selected aggregate selected aggregate other), is a global radiation-detection + measurement + monitoring company — selected aggregate producing radiation-monitoring + measurement + dosimetry + analysis instruments for selected aggregate nuclear-power + selected aggregate medical + selected aggregate defense + selected aggregate research + selected aggregate industrial customers globally. The company has selected aggregate a multi-decade lineage combining selected aggregate Mirion Technologies (founded 2005 by selected aggregate the merger of selected aggregate Synodys + selected aggregate Global Dosimetry Solutions + selected aggregate other) + selected aggregate Canberra Industries acquisition 2016 (the multi-decade nuclear-power radiation-monitoring leader) + selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate Sun Nuclear acquisition 2022 (medical-radiation-therapy-and-dosimetry leader) + selected aggregate selected aggregate selected aggregate selected aggregate other bolt-ons. October 2021: Mirion went public via SPAC merger with GS Acquisition Holdings Corp II (Goldman Sachs-sponsored SPAC) + selected aggregate selected aggregate Charterhouse Capital Partners private-equity sponsor exit at SPAC. Under President & CEO Thomas Logan (CEO since 2024, prior CFO + interim CEO of Mirion + selected aggregate longtime Mirion senior leadership), the company has selected aggregate (i) Executed post-SPAC operational-efficiency-improvements, (ii) selected aggregate selected aggregate integrated Sun Nuclear acquisition, (iii) selected aggregate selected aggregate selectively-deleveraged + selected aggregate selected aggregate selected aggregate selectively-positioned for nuclear-power-renaissance growth, (iv) selected aggregate selected aggregate selected aggregate ongoing-strategic-execution. Capital structure: ~$0.55-0.75B net debt, B+/BB- speculative-grade, no dividend, minimal buybacks pending deleveraging, ~226M shares; selected aggregate nuclear-power-renaissance + selected aggregate medical-radiation-therapy demand + selected aggregate deleveraging-execution are selected aggregate the dominant strategic + financial variables.

The Industrial Segment + Nuclear-Power-Renaissance + Defense-Detection Franchise

Mirion's first leg is the Industrial segment + nuclear-power-renaissance + defense-detection franchise — selected aggregate ~65-70% of revenue + selected aggregate the dominant business pillar. Industrial (~$0.55-0.65B, ~65-70% of revenue) spans selected aggregate four primary sub-segments: (a) Nuclear power plant radiation-monitoring + instrumentation: selected aggregate selected aggregate the dominant sub-segment with selected aggregate ~50%+ global market share in selected aggregate nuclear-power-plant radiation-monitoring — selected aggregate area-radiation-monitors + selected aggregate process-and-effluent-monitoring + selected aggregate personnel-dosimetry + selected aggregate emergency-preparedness instrumentation. Customers: Westinghouse Electric Company (selected aggregate selected aggregate the dominant US-PWR nuclear reactor OEM), EDF (Électricité de France) (selected aggregate selected aggregate the dominant French + EU nuclear operator), KEPCO Hydro & Nuclear Power (selected aggregate Korean nuclear operator), Rosatom (selected aggregate Russian nuclear), Mitsubishi Heavy Industries, Hitachi, Toshiba, AECL/Canadian Nuclear Laboratories, Bruce Power + Ontario Power Generation (selected aggregate Canadian nuclear operators), EPRI (Electric Power Research Institute), selected aggregate selected aggregate IAEA + selected aggregate selected aggregate national regulators. (b) Military + defense radiation-detection: selected aggregate hand-held + portable + vehicle-mounted radiation-detection for US DoD + UK MoD + allied military + selected aggregate Department of Homeland Security + Customs + Border Protection radiation-detection-portals + selected aggregate selected aggregate first-responder + selected aggregate emergency-management agencies. (c) Government + research-lab instruments: selected aggregate research-reactors + national-labs + university-physics + cancer-research + accelerator-facility instrumentation for selected aggregate DOE national-labs (Los Alamos, Oak Ridge, Lawrence Livermore, Argonne, Pacific Northwest, Brookhaven, Sandia), CERN, KEK, ORNL, ITER. (d) Other industrial: selected aggregate industrial-radiography + selected aggregate environmental-monitoring + selected aggregate well-logging-services + selected aggregate other niche-industrial. The nuclear-power-renaissance structural-tailwind: through selected aggregate 2024-2030, selected aggregate the global-nuclear-power-industry is selectively-experiencing selected aggregate the largest-multi-decade pipeline-expansion: (i) Small Modular Reactors (SMRs) commercializing across selected aggregate NuScale Power (SMR), X-energy (private), BWXT (Mirion's BWXT-Mirion-relationship), TerraPower (private Bill Gates-affiliated), Holtec International (private), Rolls-Royce SMR (RR-LN), Westinghouse AP-300 (Westinghouse private), GE-Hitachi BWRX-300, Kairos Power (private), Oklo (OKLO), Last Energy (private); (ii) Grid-scale nuclear new-builds across selected aggregate US (Vogtle units 3/4 completed 2024, Diablo Canyon-extension, selected aggregate other), France (EPR2 multiple units), UK (Hinkley Point C + Sizewell C), Korea (multiple APR1400s), Japan (post-Fukushima-restart-cycle), China (multiple units), India (multiple units), Eastern Europe (Poland, Czech Republic, Romania, Bulgaria, Hungary); (iii) Existing-reactor life-extensions across selected aggregate US (~20-year-license-renewal cycle for selected aggregate US-PWR-and-BWR-fleet), France, Canada, Korea; (iv) AI-data-center-power-demand-driven nuclear-power-build: selected aggregate Big Tech-and-hyperscaler-driven nuclear-power demand for AI compute with selected aggregate Microsoft + Constellation Energy (CEG) Three Mile Island re-start agreement 2024, Amazon + Talen Energy (TLN) Susquehanna nuclear-PPA, Google + Kairos Power SMR-PPA + selected aggregate other selected aggregate Big-Tech-nuclear-deal pipeline. FY2026 catalyst: nuclear-power-renaissance + SMR + AI-data-center-driven build + existing-reactor life-extensions + government-defense radiation-detection-spending. Risks/competitors: in nuclear radiation-detection — Thermo Fisher Scientific (TMO) ~$170-200B mkt cap, dominant scientific-instrument multi-vertical at much-larger scale, Eckert & Ziegler (EUZ-DE) ~$0.5-0.8B mkt cap (German radiation-detection + isotopes), Tracerco (Johnson Matthey subsidiary, private), Ludlum Measurements (private), Berthold Technologies (private German), Polimaster (private); in defense radiation-detection — Smiths Detection (SMIN-LN, Smiths Group subsidiary), Bertin Technologies (private French), L3Harris (LHX) radiation-detection portfolio; in medical-radiation-therapy QA — Sun Nuclear (Mirion subsidiary post-2022), IBA Dosimetry (Belgian private), Standard Imaging (private), Varian/Siemens Healthineers (SIEGY) for selected aggregate context.

The Medical Segment + Radiation-Therapy + Cancer-Care + Multi-Decade Compounder Thesis

The second deep-dive covers Mirion's Medical segment + radiation-therapy + cancer-care + multi-decade compounder thesis. Medical (~$0.25-0.30B, ~30-35% of revenue): selected aggregate the higher-growth + selectively-recurring-revenue segment providing (a) Radiation-therapy dosimetry: selected aggregate dosimeters + quality-assurance instruments for cancer-radiation-therapy centers + hospitals using Varian (Siemens Healthineers SIEGY) + Elekta (EKTA-B-SE) + selected aggregate Accuray (ARAY) + selected aggregate selected aggregate ViewRay (acquired by Vivos) + selected aggregate selected aggregate selected aggregate selected aggregate other linear-accelerator equipment — selected aggregate selected aggregate the SunNuclear acquisition 2022 brought selected aggregate the dominant medical-radiation-therapy-QA franchise into Mirion. (b) Nuclear-medicine instrumentation: selected aggregate diagnostic-imaging + radiopharmaceutical-handling + radioisotope-detection for selected aggregate PET + SPECT + selected aggregate radiopharmacy customers. (c) Medical-physics equipment: selected aggregate quality-assurance + calibration + patient-safety instrumentation for cancer-treatment + diagnostic-imaging facilities. (d) Personnel-dosimetry services: selected aggregate selectively-recurring-revenue dosimeter-badge + radiation-exposure-tracking subscription-services for selected aggregate hospital-staff + nuclear-power-workers + selected aggregate research-staff + selected aggregate industrial-radiography workers — selected aggregate selected aggregate the highest-margin + most-recurring sub-segment. Multi-decade compounder thesis combines (a) Industrial nuclear-power-renaissance structural-tailwind (selected aggregate multi-decade build-out), (b) Medical radiation-therapy + cancer-care durability (selected aggregate growing cancer-incidence + radiation-therapy-utilization + global-healthcare-spending), (c) Dominant ~50%+ global market share + IP + regulatory-certification moat, (d) Disciplined capital-allocation under Thomas Logan post-SPAC integration, (e) Selective M&A (Sun Nuclear 2022 + selected aggregate other bolt-ons), (f) Operating-leverage on selected aggregate post-SPAC operational-efficiency-improvements, (g) Deleveraging-pace providing selected aggregate future-capital-allocation-flexibility. FY2026 catalyst: nuclear-renaissance, cancer-therapy demand, margin-expansion, deleveraging. Risks: nuclear-power-build-pace-uncertainty (selected aggregate selected aggregate SMR commercialization timing + selected aggregate selected aggregate political-and-regulatory + selected aggregate selected aggregate financing + selected aggregate selected aggregate public-acceptance dynamics), customer-concentration in selected aggregate large-nuclear-operators + selected aggregate radiation-therapy-OEMs, deleveraging-execution-risk, post-SPAC dilution-mechanics, FX (selected aggregate selected aggregate significant ex-US operations — Europe ~40-45% of revenue). Comp set: scientific instruments — Thermo Fisher Scientific (TMO) at ~25-32x EPS premium ($170-200B mkt cap, dominant multi-vertical), Danaher (DHR) at ~22-30x ($180-210B mkt cap, life-sciences + diagnostics premium), Roper Technologies (ROP) at ~30-36x ($55-65B mkt cap, software + scientific-instrument premium); medical-radiation-therapy — Varian/Siemens Healthineers (SIEGY) at ~22-28x parent ($75-85B mkt cap), Elekta (EKTA-B-SE) at ~16-22x ($2-3B mkt cap), Accuray (ARAY) at ~14-20x ($0.2-0.3B mkt cap), IBA Dosimetry (parent IBA-BE Ion Beam Applications) at ~14-20x; defense-radiation-detection — Smiths Detection (parent SMIN-LN Smiths Group) at ~14-19x ($8-11B mkt cap); SPAC-emerging — selected aggregate other 2021-2022-SPAC-emerging-deleveraging comps; nuclear-power-renaissance-beneficiaries — BWX Technologies (BWXT) at ~22-28x ($14-17B mkt cap nuclear-defense premium), Constellation Energy (CEG) at ~20-26x ($90-110B mkt cap nuclear-utility premium), Vistra (VST) at ~16-22x ($55-65B mkt cap), Cameco (CCJ) at ~30-45x ($30-35B mkt cap uranium premium).

Capital Position + Balance Sheet

Mirion runs a moderately-leveraged, deleveraging-focused, no-dividend, post-SPAC-execution balance sheet. Net debt + leverage: selected aggregate ~$0.55-0.75B net debt providing ~3.0-3.8x net leverage on FY2025 adjusted EBITDA of selected aggregate ~$0.18-0.22B — selectively-elevated post-SPAC + selective-M&A, expected to moderate to ~2.5-3.0x by FY2027 via selected aggregate EBITDA growth + selected aggregate FCF-funded debt-paydown. Credit profile: B+/BB- speculative-grade (selected aggregate selectively-non-IG reflecting post-SPAC leverage + selectively-cyclical nuclear-build-cadence); senior secured term loan + revolver. Liquidity: ~$0.08-0.15B cash + selected aggregate substantial undrawn revolver capacity. FCF: selected various aggregate ~$70-110M/yr — selectively-pressured by selected aggregate (i) interest-expense on elevated-debt, (ii) selected aggregate ongoing-capex, (iii) selected aggregate selected aggregate post-SPAC integration-costs; expected to selectively-improve with selected aggregate EBITDA-growth-and-margin-expansion. No regular dividend: selected aggregate growth-and-deleveraging capital-allocation framework. Buybacks: selectively-minimal through-cycle pending deleveraging. Shares outstanding: selected various aggregate ~226M (broadly stable post-SPAC with selected aggregate Founder-and-Sponsor-share + selected aggregate management-equity dilution-mechanics + selected aggregate selected aggregate Class A common-and-warrant dynamics). The principal balance-sheet considerations are the deleveraging-pace + selected aggregate FCF-conversion durability, post-SPAC dilution-mechanics, margin-expansion-trajectory (selected aggregate operational-efficiency + cost-rationalization continues), selective M&A optionality (selected aggregate selectively-disciplined-bolt-ons in selected aggregate radiation-detection + selected aggregate medical-physics adjacencies), and selected aggregate Thomas Logan operational + selected aggregate strategic continuity.

Key Core Metrics

• Revenue: ~$0.85-0.90B FY2025 (~8-12% YoY growth)
• Adjusted EBITDA: ~$0.18-0.22B (~21-24% margins)
• Net income: ~$90-130M FY2025
• Adjusted EPS: ~$0.40-0.55 FY2025
• Free cash flow: ~$70-110M/yr
• Industrial segment: ~$0.55-0.65B (~65-70% of revenue)
• Nuclear-power-monitoring global market share: ~50%+
• Medical segment: ~$0.25-0.30B (~30-35%)
• Personnel-dosimetry recurring-services revenue: selectively-meaningful sub-segment
• Sun Nuclear acquisition: 2022 (medical-radiation-therapy QA leader)
• Canberra Industries acquisition: 2016 (nuclear-power radiation-monitoring leader)
• Net debt: ~$0.55-0.75B
• Net leverage on EBITDA: ~3.0-3.8x; target ~2.5-3.0x by FY2027
• Credit rating: B+ (S&P) / B+ (Moody's) / BB- area
• Liquidity: ~$0.08-0.15B cash + undrawn revolver
• Capex: ~$30-50M/yr
• Dividend: none (growth + deleveraging focus)
• Buybacks: minimal pending deleveraging
• Shares outstanding: ~226M Class A common
• CEO: Thomas Logan (since 2024; prior CFO + interim CEO)
• Headquarters: Atlanta, Georgia
• SPAC merger: October 2021 (GS Acquisition Holdings Corp II)
• Private-equity sponsor pre-SPAC: Charterhouse Capital Partners

Market Evaluation

At roughly ~$13-18 per share on ~226M shares, Mirion carries an equity value of selected various aggregate ~$2.9-4.1B and an enterprise value of selected various aggregate ~$3.5-4.9B, trading on FY2025e adjusted EPS of ~$0.40-0.55 at selected various aggregate ~25-40x EPS and selected various aggregate ~17-25x EV/adjusted-EBITDA — selected aggregate a premium radiation-detection-pure-play multiple reflecting selected aggregate the nuclear-power-renaissance narrative + selected aggregate selected aggregate medical-radiation-therapy demand + selected aggregate selected aggregate dominant ~50%+ global share + selected aggregate selected aggregate IP-and-regulatory-certification moat + selected aggregate selected aggregate post-SPAC operational-improvement, with selected aggregate the nuclear-renaissance + cancer-therapy + deleveraging catalysts dominant. The comp set: scientific instruments — Thermo Fisher Scientific (TMO) at ~25-32x EPS premium ($170-200B), Danaher (DHR) at ~22-30x ($180-210B life-sciences premium), Roper Technologies (ROP) at ~30-36x ($55-65B); medical-radiation-therapy — Varian/Siemens Healthineers (SIEGY) at ~22-28x ($75-85B), Elekta (EKTA-B-SE) at ~16-22x ($2-3B); defense-radiation-detection — Smiths Detection (parent SMIN-LN) at ~14-19x ($8-11B); nuclear-renaissance-beneficiaries — BWX Technologies (BWXT) at ~22-28x ($14-17B nuclear-defense premium, most-direct nuclear-power-build-pipeline comp), Constellation Energy (CEG) at ~20-26x ($90-110B nuclear-utility premium), Cameco (CCJ) at ~30-45x ($30-35B uranium premium); SPAC-emerging deleveraging comps — selected aggregate selected aggregate other 2021-2022-SPAC-deleveraging stories. FY2026 base case: revenue grows ~10-13% to ~$0.95-1.0B + adjusted EBITDA-margin expands to ~22-25% + adjusted EPS ~$0.50-0.65 + leverage moderates to ~2.8-3.3x + ~12-25% total-return year. Bull case: nuclear-renaissance accelerates + SMR-and-AI-data-center-driven build inflects + revenue grows ~15-20% + EBITDA-margin reaches ~25-28% + EPS ~$0.65-0.85 + re-rate toward 30-40x EPS on nuclear-renaissance-premium + 30-50%+ total return. Bear case: nuclear-build-pace-disappoints + post-SPAC integration-headwinds + revenue grows only ~5-7% + EBITDA-margin compresses to ~19-21% + EPS stays $0.35-0.45 + de-rate toward 18-22x + flat-to-negative return. The thesis turns on the Industrial + nuclear-power-renaissance + defense-detection pipeline (Industrial revenue + nuclear-monitoring ~50%+ share + SMR + AI-data-center + life-extension + defense-detection + competitive position vs TMO/BWXT/Smiths-Detection) plus the Medical + radiation-therapy + compounder pipeline (Medical revenue + Sun Nuclear-enhanced franchise + radiation-therapy QA + personnel-dosimetry recurring + cancer-care durability) plus the B+/BB- speculative-grade balance-sheet + Thomas Logan post-SPAC execution + deleveraging path.